Examining the Cosmetics Compliance and Enforcement Landscape

Examining the Cosmetics Compliance and Enforcement Landscape – FDA Watch

Shelly and Wayne chat with Justin Prochnow, Partner in the Denver office of Greenberg Traurig. You'll hear his thoughts on what FDA could be prioritizing in cosmetics and personal care products under new FDA Commissioner Dr. Marty Makary; compliance and enforcement obstacles the agency is facing with MoCRA implementation; challenges companies are facing from class-action attorneys; the intersection of cosmetics and environmental regulation; and much more. In our headlines segment, Shelly and Wayne delve into these major developments: Pharma: FDA will not require an Advisory Committee meeting for a new fibromyalgia treatment, potentially streamlining its approval process Medical Devices: Advocacy group says FDA should regulate "dangerous" prescription software platform as a medical device Food: FDA pushes back the compliance date of the Food Safety Modernization Act Section 204(d) Cosmetics: From Fortune, beauty industry giants plead with European Union to exclude American cosmetics from tariff war In our Resource Links segment, we list key documents in our four core areas. To view these links, subscribe, or find out more information about our podcast, visit FDAWatch.net. Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at info@fdawatch.net. Music by Dvir Silver from Pixabay.

Listen on Spotify

Listen on Apple Podcasts

Shelly and Wayne chat with Justin Prochnow, Partner in the Denver office of Greenberg Traurig. You’ll hear his thoughts on what FDA could be prioritizing in cosmetics and personal care products under new FDA Commissioner Dr. Marty Makary; compliance and enforcement obstacles the agency is facing with MoCRA implementation; challenges companies are facing from class-action attorneys; the intersection of cosmetics and environmental regulation; and much more.

Headlines

Pharma: FDA will not require an Advisory Committee meeting for a new fibromyalgia treatment, potentially streamlining its approval process

Devices: Advocacy group says FDA should regulate “dangerous” prescription software platform as a medical device

Food: FDA pushes back the compliance date of the Food Safety Modernization Act Section 204(d)

Cosmetics: From Fortune, beauty industry giants plead with European Union to exclude American cosmetics from tariff war

Resource Links

Pharma: New data shows that FDA drug approvals fell last year, but up-and-comers made their presence known

Devices: FDA’s Idea Lab was helps developers to create new solutions, visualize how their medical devices may fit into the lifestyles and homes of people, as well as integrate well with other health technologies

Food: FDA launches Chemical Contaminants Transparency Tool

Cosmetics: FDA publishes summary data from mandatory registration of cosmetic product facilities and the listing of cosmetic products, as required under MoCRA

About Our Guest

Justin Prochnow

Justin Prochnow assists companies with regulatory, business, and legal needs in the beverage, food, dietary supplement, cosmetic, medical device, and OTC industries. Justin works closely with companies to ensure regulatory compliance with statutes and regulations enforced by the Food and Drug Administration, the Federal Trade Commission and other regulatory agencies. This includes the review of product labels, labeling, advertising, websites and other marketing materials. Justin assists companies with responding to governmental and regulatory actions, including FDA inspections and warning letters, FTC Civil Investigative Demands, and ASRC and NAD cases. He prepares and reviews business documents for industry members, including consulting, manufacturing, supply and distribution agreements. Justin and his team also defend industry companies from both governmental agencies and civil litigators in litigation ranging from breach of contract cases to the growing number of class actions alleging false and misleading advertising.